Speiser P - Search Results

1

Ovarian function during low-dose oral contraceptive use.

Egarter C, Putz M, Strohmer H, Speiser P, Wenzl R, Huber J. Egarter C, et al. Among authors: speiser p. Contraception. 1995 Jun;51(6):329-33. doi: 10.1016/0010-7824(95)00096-s. Contraception. 1995. PMID: 7554971 Clinical Trial.

2

The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women.

Egarter C, Geurts P, Boschitsch E, Speiser P, Huber J. Egarter C, et al. Among authors: speiser p. Acta Obstet Gynecol Scand. 1996 Apr;75(4):386-93. doi: 10.3109/00016349609033337. Acta Obstet Gynecol Scand. 1996. PMID: 8638462 Review.

3

[Therapy of infections in gynecology].

Wenisch C, Reisenberger K, Speiser P, Egarter C, Graninger W. Wenisch C, et al. Among authors: speiser p. Wien Klin Wochenschr. 1993;105(24):689-96. Wien Klin Wochenschr. 1993. PMID: 8116303 Review. German.

4

Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin.

Dittrich Ch, Sevelda P, Salzer H, Obermair A, Speiser P, Breitenecker G, Schemper M, Kaider A; Austrian Ovarian Cancer Study Group. Dittrich Ch, et al. Among authors: speiser p. Eur J Cancer. 2003 May;39(8):1129-40. doi: 10.1016/s0959-8049(03)00152-7. Eur J Cancer. 2003. PMID: 12736113 Clinical Trial.

5

Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer.

Baur M, Schernhammer E, Gneist M, Sevelda P, Speiser P, Hudec M, Dittrich Ch. Baur M, et al. Among authors: speiser p. Br J Cancer. 2005 Mar 28;92(6):1019-25. doi: 10.1038/sj.bjc.6602427. Br J Cancer. 2005. PMID: 15756278 Free PMC article. Clinical Trial.

6

Prediction of toxicity but not of clinical course by determining carboplatin exposure in patients with epithelial ovarian cancer treated with a combination of carboplatin and cisplatin.

Obermair A, Speiser P, Thoma M, Kaider A, Salzer H, Dittrich C, Sevelda P. Obermair A, et al. Among authors: speiser p. Int J Oncol. 1998 Nov;13(5):1023-30. doi: 10.3892/ijo.13.5.1023. Int J Oncol. 1998. PMID: 9772295 Clinical Trial.

7

Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy.

Mayerhofer K, Kucera E, Zeisler H, Speiser P, Reinthaller A, Sevelda P. Mayerhofer K, et al. Among authors: speiser p. Gynecol Oncol. 1997 Jan;64(1):109-13. doi: 10.1006/gyno.1996.4514. Gynecol Oncol. 1997. PMID: 8995557

8

CD-44 is not involved in the metastatic spread of ovarian cancer in vivo.

Speiser P, Wanner C, Breitenecker G, Kohlberger P, Kainz C. Speiser P, et al. Anticancer Res. 1995 Nov-Dec;15(6B):2767-9. Anticancer Res. 1995. PMID: 8669861

9

pS2 and PAI-1 in ovarian cancer: correlation to pathohistological parameters.

Speiser P, Mayerhofer K, Kucera E, Roch G, Mittelböck M, Gitsch G, Zeillinger R. Speiser P, et al. Anticancer Res. 1997 Jan-Feb;17(1B):679-83. Anticancer Res. 1997. PMID: 9066601

10

EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients.

Fischer-Colbrie J, Witt A, Heinzl H, Speiser P, Czerwenka K, Sevelda P, Zeillinger R. Fischer-Colbrie J, et al. Among authors: speiser p. Anticancer Res. 1997 Jan-Feb;17(1B):613-9. Anticancer Res. 1997. PMID: 9066588

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

538 results

Search Page

Filters